Wong Daniel H T, Li Kenneth K W
Department of Ophthalmology, United Christian Hospital, Hospital Authority, Hong Kong, China.
Department of Ophthalmology, Tseung Kwan O Hospital, Hospital Authority, Hong Kong, China.
J Clin Med. 2023 Dec 27;13(1):145. doi: 10.3390/jcm13010145.
We aimed to investigate the success rate of planned fixed quarterly aflibercept injections after three loading doses (QDA3L) to achieve stability without recurrence in neovascular age-related macular degeneration (nAMD) at a tertiary eye centre. A retrospective study was conducted over five years (2017-2021) by including all consecutive cases of nAMD treated with three initial aflibercept injections four weeks apart, followed by planned injection appointments every 12 to 16 weeks starting from week 20. The primary endpoint was to determine the proportion of patients who maintained disease inactivity at week 52 and week 104. A total of 40 eyes of 40 patients were included. The overall mean age was 80.8, with a male preponderance. The overall success rate in our study population was 52.9% and 53.6% at week 52 and week 104, respectively. The fovea remained dry at 85.3% at week 52 and 82.1% at week 104, and 85.3% and 85.7% of subjects lost fewer than 15 ETDRS letters at week 52 and week 104, respectively. While this study does not suggest the superiority of this regimen, the success and failure rates obtained in our study can be used in the counselling process for this particular fixed treatment regimen for nAMD.
我们旨在研究在一家三级眼科中心，对于新生血管性年龄相关性黄斑变性（nAMD）患者，在给予三次负荷剂量阿柏西普注射（QDA3L）后，按计划每季度固定注射阿柏西普以实现病情稳定且无复发的成功率。我们进行了一项回顾性研究，研究时间跨度为五年（2017 - 2021年），纳入了所有连续的nAMD病例，这些患者最初每隔四周接受三次阿柏西普注射，从第20周开始每12至16周进行一次计划内的注射预约。主要终点是确定在第52周和第104周病情保持静止的患者比例。共纳入了40例患者的40只眼。总体平均年龄为80.8岁，男性居多。在我们的研究人群中，第52周和第104周的总体成功率分别为52.9%和53.6%。在第52周时，85.3%的黄斑中心凹保持干燥，在第104周时为82.1%；在第52周和第104周时，分别有85.3%和85.7%的受试者视力下降少于15个ETDRS字母。虽然本研究并未表明该治疗方案具有优越性，但我们研究中获得的成功率和失败率可用于针对nAMD这种特定固定治疗方案的咨询过程。
